Analysis of status and countermeasures of cancer incidence and mortality in China

Cancer is the leading cause of human deaths in the world and produces serious economic burdens. On September 12, 2018, the academic journal A Cancer Journal for Clinicians published an article about the latest statistics of cancers worldwide, which provided a status report on the global burden of 36 cancers in 185 countries worldwide. Cancer has also become a serious public health problem in China and caused more and more attention of the government and people in recent years. This review analyzes the incidence, mortality and prevalent trend of cancers in China, discusses the reasons behind this status, and reviews the potential countermeasures for cancer prevention and control in China.

[1]  Qinghua Zhou,et al.  Lung cancer incidence and mortality in China, 2011 , 2015, Thoracic cancer.

[2]  APOBEC3B and IL-6 form a positive feedback loop in hepatocellular carcinoma cells , 2017, Science China Life Sciences.

[3]  Jie He,et al.  Cancer incidence and mortality in China, 2014. , 2018, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[4]  B. Katzenellenbogen,et al.  Endocrine treatment in breast cancer: Cure, resistance and beyond. , 2016, Cancer treatment reviews.

[5]  C. Murray,et al.  Cigarette smoking prevalence in US counties: 1996-2012 , 2014, Population Health Metrics.

[6]  Ning Wang,et al.  Cancer survival in China, 2003–2005: A population‐based study , 2015, International journal of cancer.

[7]  S. Loi,et al.  Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy , 2011, Proceedings of the National Academy of Sciences.

[8]  Kathleen A Cronin,et al.  Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics , 2018, Cancer.

[9]  Chuang Chen,et al.  Characteristics of breast cancer in Central China, literature review and comparison with USA. , 2016, Breast.

[10]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[11]  Anne M Wallace,et al.  Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. , 2016, The New England journal of medicine.

[12]  M. Zhou,et al.  Long non-coding RNA LOC284454 promotes migration and invasion of nasopharyngeal carcinoma via modulating the Rho/Rac signaling pathway , 2018, Carcinogenesis.

[13]  Zhi-Feng Chen,et al.  Long-Term Follow-Up of a Community Assignment, One-Time Endoscopic Screening Study of Esophageal Cancer in China. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Kunwei Shen,et al.  Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study , 2016, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[15]  B Rachet,et al.  Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data , 2011, Lancet.

[16]  Lei Li,et al.  Formation and repair of DNA-protein crosslink damage , 2017, Science China Life Sciences.

[17]  K. Boér.  Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer , 2016, OncoTargets and therapy.

[18]  Xiaoling Li,et al.  BRD7 plays an anti-inflammatory role during early acute inflammation by inhibiting activation of the NF-кB signaling pathway , 2016, Cellular and Molecular Immunology.

[19]  Zhi-cai Liu,et al.  Esophageal/gastric cancer screening in high-risk populations in Henan Province, China. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[20]  J. Cookson.  Cancer survival , 2000, The Lancet.

[21]  Qiaoni Shi,et al.  Interplay between TGF-β signaling and receptor tyrosine kinases in tumor development , 2017, Science China Life Sciences.

[22]  Xiaoping Zhou,et al.  STING-mediated DNA sensing in cancer immunotherapy , 2017, Science China Life Sciences.

[23]  M. Zhou,et al.  BRD7 inhibits the Warburg effect and tumor progression through inactivation of HIF1α/LDHA axis in breast cancer , 2018, Cell Death & Disease.

[24]  Alan D. Lopez,et al.  Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010 , 2013, The Lancet.

[25]  Lieping Chen,et al.  A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization , 2018, Cell.

[26]  Ning Wang,et al.  Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. , 2018, The Lancet. Global health.

[27]  S. Dey,et al.  CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. , 2013, Cancer cell.

[28]  Hong Liu,et al.  Targeting sphingosine-1-phosphate signaling for cancer therapy , 2017, Science China Life Sciences.

[29]  Jun Wang,et al.  Challenges to effective cancer control in China, India, and Russia. , 2014, The Lancet. Oncology.

[30]  Alan D. Lopez,et al.  Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013 , 2016, The Lancet.

[31]  H. Wong,et al.  Outcome-based health equity across different social health insurance schemes for the elderly in China , 2015, BMC Health Services Research.

[32]  Ling Wang,et al.  Comparison of Clinicopathological Features and Treatments between Young (≤40 Years) and Older (>40 Years) Female Breast Cancer Patients in West China: A Retrospective, Epidemiological, Multicenter, Case Only Study , 2016, PloS one.

[33]  W. Xiong,et al.  miR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN/AKT pathway in nasopharyngeal carcinoma , 2016, Cell Death and Disease.

[34]  Hong Bu,et al.  China national lung cancer screening guideline with low-dose computed tomography (2015 version) , 2015, Thoracic cancer.

[35]  Melissa Matz,et al.  Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.

[36]  Jie He,et al.  [Trend analysis and projection of cancer incidence in China between 1989 and 2008]. , 2012, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[37]  Jie He,et al.  Cancer incidence and mortality in China, 2013. , 2017, Cancer letters.

[38]  Hengjin Dong,et al.  The impact of expanded health system reform on governmental contributions and individual copayments in the new Chinese rural cooperative medical system. , 2016, The International journal of health planning and management.

[39]  Ahmedin Jemal,et al.  Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States , 2018, CA: a cancer journal for clinicians.

[40]  M. Hung,et al.  The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy , 2017, Science China Life Sciences.

[41]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[42]  BRD7 expression and c-Myc activation forms a double-negative feedback loop that controls the cell proliferation and tumor growth of nasopharyngeal carcinoma by targeting oncogenic miR-141 , 2018, Journal of experimental & clinical cancer research : CR.

[43]  V. Jordan,et al.  Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women’s Health , 2018, Endocrinology.

[44]  P. Yuan,et al.  Progress in targeted therapy for breast cancer , 2018, Chronic diseases and translational medicine.

[45]  D. Whiteman,et al.  How many cancer cases and deaths are potentially preventable? Estimates for Australia in 2013 , 2018, International journal of cancer.

[46]  Jie He,et al.  Annual report on status of cancer in China, 2010. , 2014, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[47]  X. Zou.  Epidemic trend, screening, and early detection and treatment of cancer in Chinese population , 2017, Cancer biology & medicine.

[48]  A. Brufsky,et al.  Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. , 2018, The oncologist.

[49]  Rebecca L. Siegel Mph,et al.  Cancer statistics, 2018 , 2018 .

[50]  Wanqing Chen,et al.  [Trend analysis of the changes of male/female, urban/rural incidences and average age of cancer patients in China 1989-2008]. , 2014, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[51]  Shao-Yi Huang,et al.  Association of the Asp312Asn and Lys751Gln polymorphisms in the XPD gene with the risk of non-Hodgkin’s lymphoma: evidence from a meta-analysis , 2015, Chinese journal of cancer.

[52]  Wanqing Chen,et al.  Breast cancer in China. , 2014, The Lancet. Oncology.